Clinical data | |
---|---|
Pronunciation | /rɛmˈdɛsɪvɪər/ rem-DESS-i-veer |
Trade names | Veklury |
Other names | GS-5734, RDV |
AHFS/Drugs.com | Monograph |
MedlinePlus | a620033 |
License data |
|
Pregnancy category | |
Routes of administration | Intravenous |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.302.974 |
Chemical and physical data | |
Formula | C27H35N6O8P |
Molar mass | 602.585 g·mol−1 |
3D model (JSmol) | |
| |
|
Remdesivir, sold under the brand name Veklury,[13][14] is a broad-spectrum antiviral medication developed by the biopharmaceutical company Gilead Sciences.[15] It is administered via injection into a vein.[16][17] During the COVID‑19 pandemic, remdesivir was approved or authorized for emergency use to treat COVID‑19 in numerous countries.[18]
Remdesivir was originally developed to treat hepatitis C,[19] and was subsequently investigated for Ebola virus disease and Marburg virus infections[20] before being studied as a post-infection treatment for COVID‑19.[21]
Remdesivir is a prodrug that is intended to allow intracellular delivery of GS-441524 monophosphate and subsequent biotransformation into GS-441524 triphosphate, a ribonucleotide analogue inhibitor of viral RNA polymerase.[22]
The most common side effect in healthy volunteers is raised blood levels of liver enzymes.[13] The most common side effect in people with COVID‑19 is nausea.[13] Side effects may include liver inflammation and an infusion-related reaction with nausea, low blood pressure, and sweating.[23]
The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.[24]